Chemokine (C-C motif) receptor 5 Is an important pathological regulator in the development and maintenance of neuropathic pain

Anesthesiology

Volumn 120, Issue 6, 2014, Pages 1491-1503

  Matsushita, Katsuyuki ^a   Tozaki Saitoh, Hidetoshi ^b   Kojima, Chinami ^b   Masuda, Takahiro ^b   Tsuda, Makoto ^b   Inoue, Kazuhide ^b   Hoka, Sumio ^a  

^a KYUSHU UNIVERSITY   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR; CHEMOKINE RECEPTOR CCR5 ANTAGONIST; CHEMOKINE RECEPTOR CX3CR1;

ALLODYNIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; HOT PLATE TEST; IMMUNOHISTOCHEMISTRY; IN SITU HYBRIDIZATION; MALE; NEUROPATHIC PAIN; NONHUMAN; PRIORITY JOURNAL; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPINAL NERVE; VON FREY TEST;

ANIMALS; CHEMOKINE CCL3; MALE; MICE; NEURALGIA; PAIN MEASUREMENT; RATS; RATS, WISTAR; RECEPTORS, CCR5; RNA, MESSENGER; SPINAL CORD;

EID: 84901640058     PISSN: 00033022     EISSN: 15281175     Source Type: Journal    
DOI: 10.1097/ALN.0000000000000190     Document Type: Article

References (40)

1. Baron R: Mechanisms of disease: Neuropathic pain-A clinical perspective. Nat Clin Pract Neurol 2006; 2:95-106
2. Bouhassira D, Lantéri-Minet M, Attal N, Laurent B, Touboul C: Prevalence of chronic pain with neuropathic characteristics in the general population. Pain 2008; 136:380-7
3. Torrance N, Smith BH, Bennett MI, Lee AJ: The epidemiology of chronic pain of predominantly neuropathic origin. Results from a general population survey. J Pain 2006; 7:281-9
4. Scholz J, Woolf CJ: Can we conquer pain? Nat Neurosci 2002; 5(suppl):1062-7
5. Woolf CJ, Mannion RJ: Neuropathic pain: Aetiology, symptoms, mechanisms, and management. Lancet 1999; 353:1959-64
6. Costigan M, Scholz J, Woolf CJ: Neuropathic pain: A maladaptive response of the nervous system to damage. Annu Rev Neurosci 2009; 32:1-32
7. Woolf CJ, Salter MW: Neuronal plasticity: Increasing the gain in pain. Science 2000; 288:1765-9
8. McMahon SB, Malcangio M: Current challenges in glia-pain biology. Neuron 2009; 64:46-54
9. Scholz J, Woolf CJ: The neuropathic pain triad: Neurons, immune cells and glia. Nat Neurosci 2007; 10:1361-8
10. Tsuda M, Inoue K, Salter MW: Neuropathic pain and spinal microglia: A big problem from molecules in "small" glia. Trends Neurosci 2005; 28:101-7
11. Tsuda M, Shigemoto-Mogami Y, Koizumi S, Mizokoshi A, Kohsaka S, Salter MW, Inoue K: P2X4 receptors induced in spinal microglia gate tactile allodynia after nerve injury. Nature 2003; 424:778-83
12. Watkins LR, Milligan ED, Maier SF: Glial activation: A driving force for pathological pain. Trends Neurosci 2001; 24:450-5
13. Abbadie C: Chemokines, chemokine receptors and pain. Trends Immunol 2005; 26:529-34
14. Abbadie C, Bhangoo S, De Koninck Y, Malcangio M, Melik-Parsadaniantz S, White FA: Chemokines and pain mechanisms. Brain Res Rev 2009; 60:125-34
15. Charo IF, Ransohoff RM: The many roles of chemokines and chemokine receptors in inflammation. N Engl J Med 2006; 354:610-21
16. Ransohoff RM: Chemokines and chemokine receptors: Standing at the crossroads of immunobiology and neurobiology. Immunity 2009; 31:711-21
17. Saika F, Kiguchi N, Kobayashi Y, Fukazawa Y, Kishioka S: CC-chemokine ligand 4/macrophage inflammatory protein-1β participates in the induction of neuropathic pain after peripheral nerve injury. Eur J Pain 2012; 16:1271-80
18. Lee YK, Choi DY, Jung YY, Yun YW, Lee BJ, Han SB, Hong JT: Decreased pain responses of C-C chemokine receptor 5 knockout mice to chemical or inflammatory stimuli. Neuropharmacology 2013; 67:57-65
19. Kiguchi N, Kobayashi Y, Saika F, Kishioka S: Epigenetic upregulation of CCL2 and CCL3 via histone modifications in infiltrating macrophages after peripheral nerve injury. Cytokine 2013; 64:666-72
20. Dansereau MA, Gosselin RD, Pohl M, Pommier B, Mechighel P, Mauborgne A, Rostene W, Kitabgi P, Beaudet N, Sarret P, Melik-Parsadaniantz S: Spinal CCL2 pronociceptive action is no longer effective in CCR2 receptor antagonist-treated rats. J Neurochem 2008; 106:757-69
21. Biber K, Tsuda M, Tozaki-Saitoh H, Tsukamoto K, Toyomitsu E, Masuda T, Boddeke H, Inoue K: Neuronal CCL21 up-regulates microglia P2X4 expression and initiates neuropathic pain development. EMBO J 2011; 30:1864-73
22. Kiguchi N, Kobayashi Y, Maeda T, Saika F, Kishioka S: CC-chemokine MIP-1α in the spinal cord contributes to nerve injury-induced neuropathic pain. Neurosci Lett 2010; 484:17-21
23. Kiguchi N, Maeda T, Kobayashi Y, Fukazawa Y, Kishioka S: Macrophage inflammatory protein-1alpha mediates the development of neuropathic pain following peripheral nerve injury through interleukin-1beta up-regulation. Pain 2010; 149:305-15
24. Kim SH, Chung JM: An experimental model for peripheral neuropathy produced by segmental spinal nerve ligation in the rat. Pain 1992; 50:355-63
25. Tsuda M, Masuda T, Kitano J, Shimoyama H, Tozaki-Saitoh H, Inoue K: IFN-gamma receptor signaling mediates spinal microglia activation driving neuropathic pain. Proc Natl Acad Sci USA 2009; 106:8032-7
26. Chaplan SR, Bach FW, Pogrel JW, Chung JM, Yaksh TL: Quantitative assessment of tactile allodynia in the rat paw. J Neurosci Methods 1994; 53:55-63
27. Kiguchi N, Kobayashi Y, Maeda T, Fukazawa Y, Tohya K, Kimura M, Kishioka S: Epigenetic augmentation of the macrophage inflammatory protein 2/C-X-C chemokine receptor type 2 axis through histone H3 acetylation in injured peripheral nerves elicits neuropathic pain. J Pharmacol Exp Ther 2012; 340:577-87
28. Okamoto M, Suzuki T, Watanabe N: Modulation of inflammatory pain in response to a CCR2/CCR5 antagonist in rodent model. J Pharmacol Pharmacother 2013; 4:208-10
29. Padi SS, Shi XQ, Zhao YQ, Ruff MR, Baichoo N, Pert CB, Zhang J: Attenuation of rodent neuropathic pain by an orally active peptide, RAP-103, which potently blocks CCR2-and CCR5-mediated monocyte chemotaxis and inflammation. Pain 2012; 153:95-106
30. Echeverry S, Shi XQ, Zhang J: Characterization of cell proliferation in rat spinal cord following peripheral nerve injury and the relationship with neuropathic pain. Pain 2008; 135:37-47
31. Raghavendra V, Tanga F, DeLeo JA: Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy. J Pharmacol Exp Ther 2003; 306:624-30
32. Tozaki-Saitoh H, Tsuda M, Miyata H, Ueda K, Kohsaka S, Inoue K: P2Y12 receptors in spinal microglia are required for neuropathic pain after peripheral nerve injury. J Neurosci 2008; 28:4949-56
33. Hickman SE, Kingery ND, Ohsumi TK, Borowsky ML, Wang LC, Means TK, El Khoury J: The microglial sensome revealed by direct RNA sequencing. Nat Neurosci 2013; 16:1896-905
34. Masuda T, Tsuda M, Yoshinaga R, Tozaki-Saitoh H, Ozato K, Tamura T, Inoue K: IRF8 is a critical transcription factor for transforming microglia into a reactive phenotype. Cell Rep 2012; 1:334-40
35. Bannert N, Craig S, Farzan M, Sogah D, Santo NV, Choe H, Sodroski J: Sialylated O-glycans and sulfated tyrosines in the NH2-terminal domain of CC chemokine receptor 5 contribute to high affinity binding of chemokines. J Exp Med 2001; 194:1661-73
36. Lieberman-Blum SS, Fung HB, Bandres JC: Maraviroc: A CCR5-receptor antagonist for the treatment of HIV-1 infection. Clin Ther 2008; 30:1228-50
37. Freynhagen R, Bennett MI: Diagnosis and management of neuropathic pain. BMJ 2009; 339:b3002
38. Nightingale S: The neuropathic pain market. Nat Rev Drug Discov 2012; 11:101-2
39. Walker DK, Abel S, Comby P, Muirhead GJ, Nedderman AN, Smith DA: Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV. Drug Metab Dispos 2005; 33:587-95
40. Walker DK, Bowers SJ, Mitchell RJ, Potchoiba MJ, Schroeder CM, Small HF: Preclinical assessment of the distribution of maraviroc to potential human immunodeficiency virus (HIV) sanctuary sites in the central nervous system (CNS) and gut-associated lymphoid tissue (GALT). Xenobiotica 2008; 38:1330-9